Researchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in ...
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer ...
Novocure’s positive phase 3 results boost pancreatic cancer treatment prospects. Read why NVCR stock is worth watching with ...
Patients with locally advanced pancreatic cancer demonstrated a two-month difference in survival with tumor-treating fields ...
There's no routine screening test for pancreatic cancer, and symptoms can be mistaken for common illnesses.
NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer.
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary ...
The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...
Novocure’s TTFields therapy combined with chemo improved overall survival by 16.2 months compared to 14.16 months with chemo ...
Oncosil Medical's investors have been promised a “catalyst rich” 2025 and 2026, including expected filings to the local TGA ...
StudyFinds' Dr. Faith Coleman speaks with the doctor testing a new vitamin C treatment that may double the survival time of ...
The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a ...